Literature DB >> 28778440

Characterization of naïve, memory and effector T cells in progressive multiple sclerosis.

Birgitte Romme Nielsen1, Rikke Ratzer2, Lars Börnsen2, Marina Rode von Essen2, Jeppe Romme Christensen2, Finn Sellebjerg2.   

Abstract

We characterized naïve, central memory (CM), effector memory (EM) and terminally differentiated effector memory (TEMRA) CD4+ and CD8+ T cells and their expression of CD49d and CD26 in peripheral blood in patients with multiple sclerosis (MS) and healthy controls. CD26+ CD28+ CD4+ TEMRA T cells were increased in all subtypes of MS, and CD26+ CD28+ CD8+ TEMRA T cells were increased in relapsing-remitting and secondary progressive MS. Conversely, in progressive MS, CD49d+ CM T cells were decreased and natalizumab increased the circulating number of all six subsets but reduced the frequency of most subsets expressing CD49d and CD26.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CD26; CD49; Memory; Natalizumab; Progressive MS; T cells

Mesh:

Substances:

Year:  2017        PMID: 28778440     DOI: 10.1016/j.jneuroim.2017.06.001

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  7 in total

1.  JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus.

Authors:  Maria A Zingaropoli; Marco Iannetta; Simona Pontecorvo; Elena Anzivino; Carla Prezioso; Donatella Maria Rodio; Manuela Morreale; Alessandra D'Abramo; Alessandra Oliva; Miriam Lichtner; Antonio Cortese; Marco Frontoni; Valeria Pietropaolo; Ada Francia; Claudio M Mastroianni; Vincenzo Vullo; Maria R Ciardi
Journal:  Biomed Res Int       Date:  2018-02-27       Impact factor: 3.411

Review 2.  Memory CD4+ T Cells in Immunity and Autoimmune Diseases.

Authors:  Itay Raphael; Rachel R Joern; Thomas G Forsthuber
Journal:  Cells       Date:  2020-02-25       Impact factor: 6.600

3.  Anti-CD20 therapy depletes activated myelin-specific CD8+ T cells in multiple sclerosis.

Authors:  Joseph J Sabatino; Michael R Wilson; Peter A Calabresi; Stephen L Hauser; Jonathan P Schneck; Scott S Zamvil
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-20       Impact factor: 11.205

4.  Short and Long Term Clinical and Immunologic Follow up after Bone Marrow Mesenchymal Stromal Cell Therapy in Progressive Multiple Sclerosis-A Phase I Study.

Authors:  Ellen Iacobaeus; Nadir Kadri; Katia Lefsihane; Erik Boberg; Caroline Gavin; Anton Törnqvist Andrén; Anders Lilja; Lou Brundin; Katarina Le Blanc
Journal:  J Clin Med       Date:  2019-12-02       Impact factor: 4.241

Review 5.  Molecular Mechanisms of Immunosenescene and Inflammaging: Relevance to the Immunopathogenesis and Treatment of Multiple Sclerosis.

Authors:  Océane Perdaens; Vincent van Pesch
Journal:  Front Neurol       Date:  2022-02-25       Impact factor: 4.003

6.  Proinsulin-specific T regulatory cells may control immune responses in type 1 diabetes: implications for adoptive therapy.

Authors:  Mateusz Gliwiński; Dorota Iwaszkiewicz-Grześ; Anna Wołoszyn-Durkiewicz; Monika Tarnowska; Magdalena Żalińska; Matylda Hennig; Hanna Zielińska; Anna Dukat-Mazurek; Joanna Zielkowska-Dębska; Maciej Zieliński; Anna Jaźwińska-Curyłło; Radosław Owczuk; Przemysława Jarosz-Chobot; Artur Bossowski; Agnieszka Szadkowska; Wojciech Młynarski; Natalia Marek-Trzonkowska; Grażyna Moszkowska; Janusz Siebert; Małgorzata Myśliwiec; Piotr Trzonkowski
Journal:  BMJ Open Diabetes Res Care       Date:  2020-02

7.  Acquisition of New Migratory Properties by Highly Differentiated CD4+CD28null T Lymphocytes in Rheumatoid Arthritis Disease.

Authors:  Beatriz Rioseras; Marco Antonio Moro-García; Alejandra García-Torre; Eva Bueno-García; Rocio López-Martínez; Maria Iglesias-Escudero; Roberto Diaz-Peña; Patricia Castro-Santos; Miguel Arias-Guillén; Rebeca Alonso-Arias
Journal:  J Pers Med       Date:  2021-06-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.